SL-501, a Next-Generation Targeted Therapy Directed at the IL-3 Receptor, Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma
SL-501, a Next-Generation Targeted Therapy Directed at the IL-3 Receptor, Possesses Preclinical Anti-tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma. ASH 2014.
